Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: Observational cohort study

BMJ (Online)

Volumn 343, Issue 7817, 2011, Pages

  Wisnivesky, Juan P ^a   Smith, Cardinale B ^a   Packer, Stuart ^a   Strauss, Gary M ^b   Lurslurchachai, Linda ^a   Federman, Alex ^a   Halm, Ethan A ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NAVELBINE; PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT;

AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; DEHYDRATION; DRUG FEVER; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPENSITY SCORE; THROMBOCYTOPENIA; VOMITING; ADJUVANT CHEMOTHERAPY; COMPARATIVE STUDY; LUNG TUMOR; METHODOLOGY; POSTOPERATIVE CARE; REGISTER; RISK FACTOR; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PLATINUM COMPOUNDS; POSTOPERATIVE CARE; REGISTRIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84859005517     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d4013     Document Type: Article

References (49)

1. Ries LAG, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, et al. SEER cancer statistics review, 1975-2003. http://seer.cancer.gov/csr/1975-2003/.
2. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997;80:1273-83. (Pubitemid 27407230)
3. Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 2010;5:29-33.
4. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-62.
5. Wisnivesky JP, Yankelevitz D, Henschke CI. The effect of tumor size on curability of stage I non-small cell lung cancers. Chest 2004;126:761-5. (Pubitemid 39258029)
6. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7. (Pubitemid 27260107)
7. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-27. (Pubitemid 44283661)
8. Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-51.
9. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97. (Pubitemid 41007845)
10. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60. (Pubitemid 38101630)
11. Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267-77.
12. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 2005;23:4999-5006. (Pubitemid 46224006)
13. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004;22:3860-7. (Pubitemid 41079866)
14. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
15. Sedrakyan A, Van Der Meulen J, O'Byrne K, Prendiville J, Hill J, Treasure T. Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2004;128:414-9. (Pubitemid 39194698)
16. Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007;25:5506-18. (Pubitemid 350232227)
17. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453-61. (Pubitemid 37279330)
18. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MK, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173-82. (Pubitemid 38759943)
19. National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Program Limited-Use Data (1973-2006).
20. Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care 2006;44:921-8. (Pubitemid 44454569)
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
22. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007;17:584-90. (Pubitemid 47096709)
23. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-67. (Pubitemid 32007842)
24. Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care 2002;40(suppl 8):43-8.
25. Brailer DJ, Kroch E, Pauly MV, Huang J. Comorbidity-adjusted complication risk: a new outcome quality measure. Med Care 1996;34:490-505. (Pubitemid 126433251)
26. Iezzoni LI, Daley J, Heeren T, Foley SM, Fisher ES, Duncan C, et al. Identifying complications of care using administrative data. Med Care 1994;32:700-15.
27. Kalish RL, Daley J, Duncan CC, Davis RB, Coffman GA, Iezzoni LI. Costs of potential complications of care for major surgery patients. Am J Med Qual 1995;10:48-54.
28. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care 2002;40(suppl 8):49-54.
29. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002;20:4636-42. (Pubitemid 36025279)
30. Kates M, Swanson S, Wisnivesky JP. Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer <=1cm in size: a review of SEER data. Chest 2011;139:491-6.
31. Wisnivesky JP, Halm E, Bonomi M, Powell C, Bagiella E. Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer. Am J Respir Crit Care Med 2010;181:264-9.
32. Wei L, Lin D, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989;84:1065-3.
33. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998;54:948-63. (Pubitemid 28429289)
34. Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, et al. Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 2001;85:1634-9. (Pubitemid 34081505)
35. Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D. Performance status score: do patients and their oncologists agree? Br J Cancer 2003;89:1022-7. (Pubitemid 37239205)
36. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 2001;19:1064-70. (Pubitemid 32176282)
37. Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000;117:1239-46. (Pubitemid 30321574)
38. Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study. J Clin Oncol 2007;25:1553-61. (Pubitemid 46733082)
39. Fruh M, Rolland E, Pignon JP, Seymour L, Ding K, Tribodet H, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 2008;26:3573-81.
40. Gridelli C, Shepherd FA. Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 2005;128:947-57. (Pubitemid 41140531)
41. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(suppl 8):3-18.
42. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31:732-48.
43. Maas KW, El Sharouni SY, Smit EF, Schramel FM. Sequencing chemotherapy, radiotherapy and surgery in combined modality treatment of stage III nonsmall cell lung cancer. Curr Opin Pulm Med 2007;13:297-304. (Pubitemid 46847295)
44. Chu DT, Kim SW, Kuo HP, Ozacar R, Salajka F, Krishnamurthy S, et al. Patient attitudes towards chemotherapy as assessed by patient versus physician: a prospective observational study in advanced non-small cell lung cancer. Lung Cancer 2007;56:433-43. (Pubitemid 46695856)
45. List MA, Rutherford JL, Stracks J, Pauloski BR, Logemann JA, Lundy D, et al. Prioritizing treatment outcomes: head and neck cancer patients versus nonpatients. Head Neck 2004;26:163-70. (Pubitemid 38160450)
46. Tsevat J, Dawson NV, Wu AW, Lynn J, Soukup JR, Cook EF, et al. Health values of hospitalized patients 80 years or older. HELP Investigators. Hospitalized Elderly Longitudinal Project. JAMA 1998;279:371-5.
47. Balmer CE, Thomas P, Osborne RJ. Who wants second-line, palliative chemotherapy? Psychooncology 2001;10:410-8. (Pubitemid 32904005)
48. Hirose T, Horichi N, Ohmori T, Kusumoto S, Sugiyama T, Shirai T, et al. Patients preferences in chemotherapy for advanced non-small-cell lung cancer. Intern Med 2005;44:107-13. (Pubitemid 40372688)
49. Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990;300:1458-60. (Pubitemid 20195333)